Quest Exercises Option on Clinical Genomics Colon Cancer Markers | GenomeWeb

NEW YORK (GenomeWeb News) – Australian firm Clinical Genomics today said that Quest Diagnostics has exercised an option to use the firm's gene-based biomarkers in the development of new tests for colon cancer.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: role for epigenetic in neuronal excitability, and more.

The new Office of Research Integrity director is grappling with complaints from her staff, according to ScienceInsider.

Italian researchers link SNPs in the PDSS2 gene to coffee consumption in a new paper.

A gene-editing ban has been interpreted to include mitochondrial transfer, Technology Review reports.